Recall report: BRP Pharma pulls 47 bottles of generic diuretic spironolactone after mixing different strength pills
11 Mar 2021
It’s been a relatively quiet year for drug recalls with the FDA facing a work backlog, but that doesn’t mean the agency isn’t watching for offenders. Now, a generic diuretic maker is being forced to withdraw after mixing doses of its meds in the same bottles.
Bryant Ranch Prepack (BRP) has
recalled
47 bottles across four lots of spironolactone tables due to incorrect labeling of the drug’s strength on its packaging, the FDA said this week.
The agency said prepackaged bottles labeled spironolactone 50 mg may contain spironolactone 25 mg tablets, and prepackaged bottles of spironolactone 25 mg may contain spironolactone 50 mg tablets.
A diuretic used to treat high-blood pressure, spironolactone taken in less-than-prescribed doses may cause an elevation in blood pressure or edema over time. The FDA warned patients could experience a decrease in potassium if taking half of the expected dose, which could lead to hypokalemia, a condition associated with cardiac arrhythmias.
Patients who take double their prescribed dose could experience an increase in potassium, which could be life threatening, the agency said. As of Tuesday, BRP had not received any side-effect reports. The lots and expirations dates for the recall include:
It’s been a quiet year for recalls at the FDA amid an agency-wide pinch for resources and a
chronic backlog
of site inspections that are often the precursor for recalls.
Last month, Apotex
launched
a voluntary recall of two batches of the blood thinner injection enoxaparin sodium this week after discovering that some syringes were mislabeled and could’ve resulted in patients accidentally getting more of the drug than needed. Blamed on a packaging error, Apotex said the discrepancy was discovered through a customer complaint investigation.
A few days earlier, Nostrum Laboratories
pulled
one lot of metformin HCl extended release tablets, USP 750 mg, a Type 2 diabetes drug (the generic equivalent to Glucophage tablets) after testing discovered elevated levels of nitrosamine, the probable carcinogen. It was an expansion of Nostrum’s earlier recall and the latest of a string of drugmakers to pull their generic versions of the Type 2 diabetes meds off shelves based on carcinogen concerns.
Organizations
Indications
Targets
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.